Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about AnaptysBio, Inc.
AnaptysBio, Inc. News
AnaptysBio, Inc. Quantitative Score
About AnaptysBio, Inc.
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
AnaptysBio, Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
AnaptysBio, Inc. Financials
Table Compare
Compare ANAB metrics with: | |||
|---|---|---|---|
Earnings & Growth | ANAB | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | ANAB | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | ANAB | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | ANAB | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
AnaptysBio, Inc. Income
AnaptysBio, Inc. Balance Sheet
AnaptysBio, Inc. Cash Flow
AnaptysBio, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Sell |
| Return on Equity | Strong Buy |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Strong Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
AnaptysBio, Inc. Executives
| Name | Role |
|---|---|
| Mr. Daniel R. Faga | President, Chief Executive Officer & Director |
| Mr. Eric J. Loumeau | Chief Legal Officer |
| Dr. Paul F. Lizzul FAAD, M.B.A., M.D., M.P.H., Ph.D. | Chief Medical Officer |
| Mr. Dennis M. Mulroy | Chief Financial Officer |
| Dr. Martin Dahl Ph.D. | Senior Vice President of Research |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Mr. Daniel R. Faga | President, Chief Executive Officer & Director | Male | 1980 | 1.02M |
| Mr. Eric J. Loumeau | Chief Legal Officer | Male | 1963 | 722K |
| Dr. Paul F. Lizzul FAAD, M.B.A., M.D., M.P.H., Ph.D. | Chief Medical Officer | 1975 | 712.56K | |
| Mr. Dennis M. Mulroy | Chief Financial Officer | Male | 1955 | 673.64K |
| Dr. Martin Dahl Ph.D. | Senior Vice President of Research | -- |
AnaptysBio, Inc. Insider Trades
| Date | 30 Sep |
| Name | LOUMEAU ERIC J |
| Role | CHIEF LEGAL OFFICER |
| Transaction | Acquired |
| Type | M-Exempt |
| Shares | 5000 |
| Date | 30 Sep |
| Name | LOUMEAU ERIC J |
| Role | CHIEF LEGAL OFFICER |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 8240 |
| Date | 30 Sep |
| Name | LOUMEAU ERIC J |
| Role | CHIEF LEGAL OFFICER |
| Transaction | Disposed |
| Type | M-Exempt |
| Shares | 5000 |
| Date | 15 Sep |
| Name | Orwin John A |
| Role | Director |
| Transaction | Acquired |
| Type | M-Exempt |
| Shares | 1300 |
| Date | 15 Sep |
| Name | Orwin John A |
| Role | Director |
| Transaction | Disposed |
| Type | M-Exempt |
| Shares | 1300 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 30 Sep | LOUMEAU ERIC J | CHIEF LEGAL OFFICER | Acquired | M-Exempt | 5000 |
| 30 Sep | LOUMEAU ERIC J | CHIEF LEGAL OFFICER | Disposed | S-Sale | 8240 |
| 30 Sep | LOUMEAU ERIC J | CHIEF LEGAL OFFICER | Disposed | M-Exempt | 5000 |
| 15 Sep | Orwin John A | Director | Acquired | M-Exempt | 1300 |
| 15 Sep | Orwin John A | Director | Disposed | M-Exempt | 1300 |